Contingent valuation: What needs to be done?

Health Economics, Policy and Law

Volumn 5, Issue 1, 2010, Pages 91-111

  Smith, Richard D ^a   Sach, Tracey H ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINGENT VALUATION; DECISION MAKING; ECONOMIC EVALUATION; EMPIRICAL RESEARCH; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEALTH SURVEY; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH SERVICE; HUMAN; UTILIZATION REVIEW;

CHOICE BEHAVIOR; COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH SERVICES NEEDS AND DEMAND; HUMANS;

EID: 77449111522     PISSN: 17441331     EISSN: 1744134X     Source Type: Journal    
DOI: 10.1017/S1744133109990016     Document Type: Review

References (58)

1. Acton, J. P. (1973), Evaluating Public Programs to Save Lives: The Case of Heart Attacks, Santa Monica: R-950-RC, RAND.
2. Acton, J. P. (1976), 'Measuring the monetary value of lifesaving programs', Law and Contemporary Problems, 40: 46-72.
3. Adler, M. D. (2006), 'QALYs and policy evaluation: a new perspective', Yale Journal of Health Policy, Law and Ethics, VI: 1-92.
4. Arrow, K., R. Solow, P. R. Portney, E. E. Leamer, R. Radner and H. Schuman (1993), 'Report of the NOAA panel of contingent valuation', Federal Register, 58: 4601-4614.
5. Bateman, I., R. T. Carson, B. Day, W. M. Hanemann, N. Hanley, T. Hett, A. Jones, G. Loomes, S. Mourato, E. Ozdemiroglu, D. W. Pearce, R. Sugden and J. Swanson (2002), Economic Valuation with Stated Preferences Techniques. A Manual, Cheltenham: Edward Elgar.
6. Bleichrodt, H. and J. Quiggin (1999), 'Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis?', Journal of Health Economics, 18(6): 681-708.
7. Buxton, M. J. (2005), 'How much are health-care systems prepared to pay to produce a QALY?', European Journal of Health Economics, 6: 285-287.
8. Byrne, M. M., K. O'malley and M. E. Suarez-Almazor (2005), 'Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis', Medical Decision Making, 25: 655-666.
9. Cookson, R. (2003), 'Willingness to pay methods in health care: a sceptical view', Health Economics, 12: 891-894.
10. Covey, J. and R. D. Smith (2006), 'How common is the "prominence effect"? Additional evidence to Whynes et al.', Health Economics, 15: 205-210.
11. Devlin, N. and D. Parkin (2004), 'Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, Health Economics, 13: 437-452.
12. Diener, A., B. O'Brien and A. Gafni (1998), 'Health care contingent valuation studies: a review and classification of the literature', Health Economics, 7: 313-326.
13. Dolan, P. and R. Edlin (2002), 'Is it really possible to build a bridge between cost- benefit analysis and cost-effectiveness analysis?', Journal of Health Economics, 21: 827-843.
14. Donaldson, C., I. Bateman, S. Chilton, M. Jones-Lee, G. Loomes, H. Metcalf, M. Mugford, A. Robinson, M. Ryan, P. Shackley, R. D. Smith, R. Sugden and J. Wildman (2003), What is the Value to Society of a QALY?, Department of Health. NCCRD, Birmingham, UK.
15. Donaldson, C., W. Brouwer, L. Gulacsi, D. Gyrd-Hansen, A. Kozierkiewicz, J. A. Olsen, A. Manca, A. Mataria, J. P. Moatti, U. Persson, J. L. Pinto Prades, M. Ryan and R. D. Smith (2006), 'European Value of a Quality Adjusted Life Year', European Union Framework, 6. http://cordis.europa.eu/fetch?CALLER5FP6- PROJ&ACTION5D& DOC51&CAT5PROJ&QUERY50121eaa95d53:22fc: 1d7ece4e&RCN584063
16. Drummond, M., H. Weatherly, K. Claxton, R. Cookson, B. Ferguson, C. Godfrey, N. Rice, M. Sculpher and A. Sowden (2007), Assessing the Challenges of Applying Standard Methods of Economic Evaluation to Public Health Interventions. http://www.york. ac.uk/phrc/D1-05-FR.pdf [3 April 2008].
17. Eichler, H. G., S. X. Kong, W. C. Gert, P. Mavros and B. Jonsson (2004), 'Use of costeffectiveness analysis in health-care resource allocation decision-making: how are costeffectiveness thresholds expected to emerge?', Value in Health, 7: 518-528.
18. Franica, D. M., D. S. Pathakb and A. Gafni (2005), 'Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey', Journal of Clinical Epidemiology, 58: 291-303.
19. Frew, E. J., D. K. Whynes and J. L. Wolstenholme (2003), 'Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats', Medical Decision Making, 23: 150-159.
20. Gafni, A. and S. Birch (2006), 'Incremental cost-effectiveness ratios (ICERs): the silence of the lambda', Social Science and Medicine, 62: 2091-2100.
21. Garber, A. M. and C. E. Phelps (1997), 'Economic foundations of cost-effectiveness analysis', Journal of Health Economics, 16(1): 1-31.
22. George, B., A. Harris and A. Mitchell (2001), 'Cost-effectiveness analysis and the consistency of decision-making. Evidence from pharmaceutical reimbursement in Australia (1991-1996)', PharmacoEconomics, 19: 1103-1109.
23. Gyrd-Hansen, D. (2003), 'Willingness to pay for a QALY', Health Economics, 12: 1049-1060.
24. Hammitt, J. K. (2002), 'How Much is a QALY Worth? Admissible Utility Functions for Health and Wealth', Working Paper, Harvard Center for Risk Analysis, Harvard University.
25. Haninger, K. and J. K. Hammitt (2006), 'Willingness to Pay for Quality Adjusted Life Years: Empirical Inconsistency between Cost-effectiveness Analysis and Economic Welfare Theory', Working Paper, Harvard Center for Risk Analysis, Harvard University.
26. Hanley, N., M. Ryan and R. Wright (2003), 'Estimating the monetary value of health care: lessons from environmental economics', Health Economics, 12: 3-16.
27. Hirth, R. A., M. E. Chernew, E. Miller, A. M. Fendrick and W. G. Weissert (2000), 'Willingness to pay for a quality-adjusted life year: in search of a standard', Medical Decision Making, 20: 332-342.
28. Johannesson, M. (1995), 'The relationship between cost-effectiveness analysis and cost- benefit analysis', Social Science and Medicine, 41: 483-489.
29. Johnson, F. R., E. E. Fries and H. S. Banzhaf (1997), 'Valuing morbidity: an integration of the willingness to pay and health status index literature', Journal of Health Economics, 16: 641-665.
30. King, J. T., J. Tsevat, J. R. Lave and M. S. Roberts (2005), 'Willingness to pay for a qualityadjusted life year: implications for societal health care resource allocation', Medical Decision Making, 25: 667-677.
31. Klose, T. (1999), 'The contingent valuation method in health care', Health Policy, 47: 97-123.
32. Mitchell, R. and R. Carson (1989), Using surveys to value public goods: The contingent valuation method, Washington, DC: Resources for the Future.
33. Mooney, G. H. (1986), Economics, Medicine and Health Care, London: Harvester Wheatsheaf.
34. Mooney, G. H. (1994), Key Issues in Health Economics, New York: Harvester Wheatsheaf.
35. National Institute of Health and Clinical Excellence (2004), Guide to theMethods of Technology Appraisal. Accessed 1 July 2008. http://www.nice.org. uk/pdf/TAP-Methods.pdf
36. Olsen, J. A. and R. D. Smith (2001), 'Theory versus practice: A review of "willingnessto-pay" in health and health care', Health Economics, 10: 39-52.
37. Phelps, C. E. and A. I. Mushlin (1991), 'On the (near) equivalence of cost-effectiveness and cost-benefit analyses', International Journal of Technology Assessment in Health Care, 7(1): 12-21.
38. Rawlins, M. and A. Culyer (2004), 'National Institute for Clinical Excellence and its value judgements', British Medical Journal, 329: 224-227.
39. Richardson, J. and R. D. Smith (2004), 'Calculating society's willingness-to-pay for a QALY: key questions for discussion', Applied Health Economics and Health Policy, 3(3): 125-126.
40. Sach, T., R. D. Smith and D. Whynes (2007), 'A "league table" of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?', PharmacoEconomics, 25: 107-127.
41. Smith, R. D. (2000), 'The discrete choice willingness-to-pay question format in Health Economics: should we adopt environmental guidelines?', Medical Decision Making, 20(2): 194-206.
42. Smith, R. D. (2001), 'The relative sensitivity of willingness-to-pay and time-trade-off to changes in health status: an empirical investigation', Health Economics, 10: 487-497.
43. Smith, R. D. (2003), 'Construction of the contingent valuation market in health care: a critical assessment', Health Economics, 12: 609-628.
44. Smith, R. D. (2004), 'The reliability of willingness to pay for changes in health status', Applied Health Economics and Health Policy, 3(1): 35-38.
45. Smith, R. D. (2005), 'Sensitivity to scale in contingent valuation: the importance of the budget constraint', Journal of Health Economics, 24: 515-529.
46. Smith, R. D. (2006), 'Its not just what you do, its the way that you do it: the effect of different payment card formats and survey administration on willingness to pay for health gain', Health Economics, 15: 281-293.
47. Smith, R. D. and J. Richardson (2005), 'Can we estimate the "social" value of a QALY? Four core issues to resolve', Health Policy, 74: 77-84.
48. Smith, R. D. (2007), 'Use, option and externality values: are contingent valuation studies in health care mis-specified?', Health Economics, 16: 861-869.
49. Smith, R. D. (2007a), 'The relationship between reliability and size of willingness to pay values: a qualitative insight', Health Economics, 16: 211-216.
50. Smith, R. D. (2007b), 'The role of "reference goods" in contingent valuation: should we help respondents to "construct" their willingness to pay?', Health Economics, 16: 1319-1332.
51. Smith, R. D. (2008), 'Contingent valuation in health care: does it matter how the "good" is described?', Health Economics, 17: 607-617.
52. Van Houtven, G., J. Powers, A. Jessup and J.-C. Yang (2006), 'Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP?', Health Economics, 15: 775-795.
53. Whynes, D. K., E. J. Frew and J. L. Wolstenholme (2003), 'A comparison of two methods for eliciting contingent valuations of colorectal cancer screening', Journal of Health Economics, 22: 555-574.
54. Whynes, D. K., E. J. Frew and J. L. Wolstenholme (2004), 'Comparing willingness-to-pay: bidding game format vs. open-ended and payment scale formats', Health Policy, 68: 289-298.
55. Whynes, D., E. Frew, Z. Philips, J. Covey and R. D. Smith (2007), 'The "prominence effect" on contingent valuation', Journal of Economic Psychology, 28: 462-476.
56. Yeung, R. Y. T. and R. D. Smith (2006), 'Can we use contingent valuation to assess the private demand for childhood immunization in developing countries? A systematic review of the literature', Applied Health Economics and Health Policy, 4: 165-173.
57. Yeung, R. Y. T., R. D. Smith and S. M. McGhee (2003), 'Willingness to pay and size of health benefit: an integrated model to test for "sensitivity to scale" ', Health Economics, 12(9): 791-796.
58. Yeung, R. Y. T., R. D. Smith, L. M. Ho, J. Johnston and G. Leung (2006), 'Empirical implications of response acquiescence in discrete-choice contingent valuation', Health Economics, 15: 1077-1089.